Pulmonary arterial hypertension is a devastating progressive disease mediated by different pathophysiologic pathways that result in progressive increase in pulmonary vascular resistance along with right ventricular failure and eventually premature death. Despite significant advances in the understanding of the underlying mechanisms and development of a number of targeted therapies, pulmonary arterial hypertension remains a challenging condition with high morbidity and mortality. New therapies are being actively sought, and early recognition remains of paramount importance. In an effort to improve the detection and management of pulmonary hypertension, the 6th World Symposium on Pulmonary Hypertension came up with most recent statements in 2018. The goal of this review is to summarize some key updates from the proceedings of the Symposium pertaining to different aspects of evaluation and management of patients with pulmonary arterial hypertension.

肺动脉高压是由不同病理生理途径介导的毁灭性进行性疾病，其导致肺血管阻力的逐步增加以及右心室衰竭并最终过早死亡。尽管在了解潜在机制和开发许多靶向疗法方面取得了重大进展，但肺动脉高压仍然是具有高发病率和死亡率的具有挑战性的疾病。正在积极寻求新疗法，​​早期识别仍然是最重要的。为了改善肺动脉高压的检测和管理，第六届世界肺动脉高压研讨会于2018年提出了最新声明。